Therefore, a majority of authoritative guidelines, such as National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), and Chinese Society of Clinical Oncology (CSCO), recommend dabrafenib in combination with trametinib as the first-line treatment for patients with advanced or metastatic NSCLC with BRAF V600E mutation (13–15). Here, BRAF is linked to non-small cell lung carcinoma.